Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Lancet Oncol. 2020 Aug 28;21(10):1317–1330. doi: 10.1016/S1470-2045(20)30452-6

Table 2.

Induction Best Overall Response

VRd KRd
(n=527) (n=526)

Category N (%) N (%)

Stringent Complete Response 21 (4%) 31 (6%)
Complete Response 57 (11%) 65 (12%)
Very Good Partial Response 263 (50%) 292 (56%)
Partial Response 103 (20%) 68 (13%)
Stable Disease 40 (8%) 34 (7%)
Progressive Disease 1 (<1%) 0 (0%)
Unevaluable/Insufficient 42 (8%) 36 (7%)

Rates N (%) N (%) Chi sq p-value

MRD Negative 38 (7%) 54 (10%) p=0.08
 (95% CI) (5%−10%) (8%−13%)
CR 78 (15%) 96 (18%) p=0.13
 (95% CI) (12%−18%) (15%−22%)
VGPR 341 (65%) 388 (74%) p<0.01
 (95% CI) (61%−69%) (70%−77%)
PR 444 (84%) 456 (87%) p=0.26
 (95% CI) (81%−87%) (84%−90%)